Onconetix (ONCO) Stock Price, News & Analysis

Company Overview

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Key Stats

• Today's Range: $4.65 to $5.93
• 50-Day Range: $0.05 to $0.09
• 52-Week Range: $4.27 to $1,190.00
• Volume: 302,077 shs
• Average Volume: 102,576 shs
• Market Capitalization: $305.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Onconetix Stock Analysis - MarketRank™

Onconetix scored higher than 9% of companies evaluated by MarketBeat, and ranked 910th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Onconetix.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Onconetix has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.42% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently decreased by 70.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Onconetix does not currently pay a dividend.

Dividend Growth

Onconetix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.42% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently decreased by 70.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.39

News Sentiment

Onconetix has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Onconetix this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for ONCO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Onconetix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Onconetix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Onconetix is held by insiders.

Percentage Held by Institutions

Only 23.89% of the stock of Onconetix is held by institutions.

ONCO Stock Analysis - Frequently Asked Questions

How have ONCO shares performed this year?

Onconetix's stock was trading at $53.55 at the beginning of 2025. Since then, ONCO stock has decreased by 91.2% and is now trading at $4.73.
View the best growth stocks for 2025 here.

How were Onconetix's earnings last quarter?

Onconetix, Inc. (NASDAQ:ONCO) issued its quarterly earnings data on Thursday, June, 12th. The company reported $21.25 earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million for the quarter.

When did Onconetix's stock split?

Onconetix shares reverse split before market open on Friday, June 13th 2025. The 1-85 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Onconetix?

Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Onconetix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI).

Company Calendar

• Last Earnings: 6/12/2025
• Today: 6/13/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCO
• Previous Symbol: NASDAQ:ONCO
• CIK: 1782107
• Web: www.bwbioinc.com
• Phone: 513-620-4101
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.41 million
• Net Margins: -2,758.89%
• Pretax Margin: -2,766.32%
• Return on Equity: N/A
• Return on Assets: -48.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: $2.52 million
• Price / Sales: 131.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.01 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 64,545,000
• Free Float: 57,174,000
• Market Cap: $332.41 million
• Optionable: N/A
• Beta: 3.50